Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C. Wainwright Global Investment Conference, which will take place May 23-26, 2022.
HC Wainwright Global Investment Conference
Date: Webcast available on demand starting at 7:00am ET May 24 – May 26, 2022
Format: Corporate overview webcast
Webcast Link: https://journey.ct.events/view/47c6f14e-2e3e-4baf-9592-cf2d6c3317f5
Replay: Available at Chemomab website at investors.chemomab.com/events
Chemomab is also participating in one-on-one meetings with investors. For more information, visit hcwevents.com/globalconference/.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in late 2022.
Contacts: | |
Investor Relations: | Media: |
Irina Koffler | Barbara Lindheim |
LifeSci Advisors, LLC | Chemomab Therapeutics |
Phone: +1 917-734-7387 | Consulting Vice President |
This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor & Public Relations, |
Strategic Communications | |
Phone: +1 917-355-9234 | |
This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$3.10 |
| Daily Change: | -0.04 -1.27 |
| Daily Volume: | 89,156 |
| Market Cap: | US$16.090M |
August 21, 2025 August 14, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
